Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item5.02. Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

Effective January30, 2017, Thomas J. Farrell resigned from his
position as a director and the President and Chief Executive
Officer of Bellicum Pharmaceuticals, Inc. (the Company). In
connection with Mr.Farrells resignation, effective January30,
2017 the Board of Directors of the Company (the Board) appointed
Richard A. Fair to serve as the Companys President and Chief
Executive Officer and, upon recommendation of the Nominating and
Governance Committee of the Board, appointed Mr.Fair to the Board
as a Class III director to hold office until the 2017 Annual
Meeting of Stockholders.

Prior to joining the Company, since January 2014, Mr.Fair served
as Senior Vice President, Therapeutic Head Oncology Global
Product Strategy at Genentech, Inc., a private biotechnology
company and subsidiary of Roche Holding AG. From April 2006 to
January 2014, Mr.Fair held other positions at Genentech,
including Vice President, Global Product Strategy Hematology
Signaling, from November 2012 through December 2013, and Vice
President, Sales Marketing, Oral Oncolytics, from May 2010 to
November 2012. Prior to Genentech, Mr.Fair held positions at
Johnson Johnson, a public pharmaceutical and medical device
company. Mr.Fair received his B.S. in computer science from the
University of Michigan and his MBA, with a dual concentration in
finance and management, from Columbia University. The Board
believes that Mr.Fairs background in the biotechnology industry
and finance, and extensive management experience at a large
biotechnology company, qualify him to serve on the Board.

In connection with Mr.Fairs appointment, the Company entered into
an employment agreement with Mr.Fair that governs the terms of
his employment with the Company. Among other things, the
employment agreement provides for (i)an annual base salary of
$535,000, (ii)a one-time cash signing bonus of $300,000, (iii)at
the sole discretion of the Board (or an authorized committee
thereof), an annual target cash performance bonus of 50% of his
annual base salary, and (iv)an option to purchase 500,000 shares
of the Companys common stock, which will vest over a four-year
period, with 25% vesting on the one-year anniversary of the
commencement of employment and the remainder vesting monthly
thereafter in equal increments for 36 months.

If Mr.Fairs employment is terminated by the Company without
cause, or if he resigns for good reason, then Mr.Fair will be
entitled under his agreement to continue to receive his annual
base salary and payment of premiums for continuation of
healthcare benefits for a period of 12 months following such
termination. In addition, Mr.Fair will be paid a lump sum cash
amount equal to his target annual performance bonus for the year
of termination, prorated based on the number of calendar days he
was employed during the year. Furthermore, if Mr.Fair is
terminated without cause or resigns for good reason within 30
days prior to or 12 months following a change in control, he will
be entitled to continue to receive his annual base salary and
payment of premiums for continuation of healthcare benefits for a
period of 18 months, a lump sum cash amount equal to the full
target performance bonus for the year of termination, and
accelerated vesting of any unvested time-based equity awards.
Mr.Fair may also be entitled to receive tax gross up payments in
the event any payments made in connection with a change in
control are subject to the excise taxes imposed by Sections 280G
and 4999 of the Internal Revenue Code. In order to receive any
severance benefits under the employment agreement, Mr.Fair is
required to execute a release of clams in favor of the Company
and comply with certain other post-employment covenants set forth
in the employment agreement.

Mr.Fair also entered into the Companys standard form of
indemnification agreement for its directors and executive
officers.

There are no family relationships between Mr.Fair and any of the
Companys current or former directors or executive officers.
Mr.Fair is not a party to any transaction that would require
disclosure under Item404(a) of Regulation S-K promulgated under
the Securities Act of 1933.

On January31, 2017, the Company issued a press release announcing
Mr.Fairs appointment. A copy of the press release is attached
hereto as Exhibit 99.1.

Item9.01 Financial Statements and Exhibits.

(d) Exhibits

About Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company’s product candidates include BPX-501, BPX-401, BPX-601 and BPX-701. BPX-501 is an adjunct T cell therapy for allogeneic hematopoietic stem cell transplantation. The Company’s CID-based technologies include CaspaCIDe, CIDeCAR and GoCAR-T.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Recent Trading Information

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) closed its last trading session up +0.74 at 12.61 with 227,744 shares trading hands.